Latest News and Press Releases

NESS ZIONA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic...

NESS ZIONA, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic...

Recently obtained FDA approval of TWYNEO® triggers milestone payment from GaldermaExclusive license agreements with Galderma for U.S. commercialization of EPSOLAY® and TWYNEOSol-Gel advancing its...

TWYNEO®, a once-daily cream treatment for acne vulgaris, is the first FDA-approved fixed-dose combination of tretinoin and benzoyl peroxideTWYNEO utilizes Sol-Gel’s proprietary microencapsulation...

NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded...

Sol-Gel investigational SGT-510 was found to be more effective than roflumilast cream, 0.3%, in a human xenograft psoriasis animal modelSol-Gel is developing tapinarof cream, 1%, aiming to offer...

NESS ZIONA, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and...

- Sol-Gel is in advanced negotiations with a potential partner regarding the commercialization of EPSOLAY® and TWYNEO®- EPSOLAY PDUFA goal date was set for April 26, 2021. Awaiting FDA’s pre-approval...

NESS ZIONA, Israel, April 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded...

• Epsolay® and Twyneo® PDUFA goal dates set for April 26, 2021 and August 1, 2021 respectively • Top-line generic product revenue of $8.7 million in fiscal 2020 • Signed additional generic product...